CompletedNot Applicable

Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or Lymphoma

United States, Spain44 participantsStarted 2018-03-01

Plain-language summary

The purpose of this study is to identify subjects with advanced solid tumors or lymphoma in which the methylthioadenosine phosphorylase (MTAP) protein has been lost.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Be ≥18 years of age.
✓. Have a histologically confirmed diagnosis of an advanced solid tumor (other than a primary CNS malignancy) or lymphoma.
✓. Have archival tumor tissue that can be provided for assessment of MTAP deletion status.
✓. Have given written informed consent to participate in this study.

Exclusion criteria

✕. Have a primary CNS malignancy (eg, GBM).
✕. Have a medical or psychological condition deemed by the Investigator likely to interfere with the subject's ability to give informed consent or participate in the study.

What they're measuring

Determination of MTAP status in tumors

Timeframe: From initiation of the Pre-Screen study until the Phase 1 study of AG-270 is activated at each study site, up to 9 months

Trial details

NCT IDNCT03361358

SponsorAgios Pharmaceuticals, Inc.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2019-09-30

View on ClinicalTrials.gov More Advanced Solid Tumors trials